BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update

About this update from Beyondspring, Inc.

[{"type":"image","alt":"BeyondSpring, Inc.","displaySize":"","headline":null,"caption":"BeyondSpring, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":255,"height":89,"url":"https://media.zenfs.com/en/globenewswire.com/06b3b5b1556b23b23891f3b41c446766"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/iztnDk_H5MGcKZO6_GJ5Qg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/06b3b5b1556b23b23891f3b41c446766","width":255,"height":89}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Presentation at IO 360° conference showed early efficacy for Plinabulin combinations in metastatic NSCLC and Hodgkin lymphoma resistant to PD‑1/L1 therapy","length":159,"tagName":"p"}]},{"val":[{"type":"text","content":"SEED’s first‑in‑class RBM39 degrader, reported at AACR 2025 for its total tumor regression data in mechanism targeted cancer indication-Ewing Sarcoma, remains on track for IND filing mid‑2025","length":196,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":355,"olType":false},{"type":"text","content":"FLORHAM PARK, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a clinical‑stage global biopharmaceutical company focused on developing cancer therapeutics, today announced its unaudited financial results for the quarter ended March 31, 2025, and provided a corporate update.","length":308,"tagName":"p"},{"type":"text","content":"“Plinabulin has now been administered to more than 700 patients with a favorable safety profile. By promoting dendritic‑cell maturation, it offers a potential option for the approximately 60 percent of cancer patients who progress on PD‑1/L1 inhibitors,” said Dr. Lan Huang, Co‑Founder, Chair, and Chief Executive Officer of BeyondSpring. “Early readouts in metastatic NSCLC and Hodgkin lymphoma who failed PD-1/L1 inhibitors showed durable responses that deserve further evaluation.”","length":494,"tagName":"p"},{"type":"text","content":"Dr. Huang added, “Within SEED, our RBM39 molecular‑glue degrader achieved complete tumor regression in mechanism-targeted Ewing sarcoma models and is on track for an IND submission mid‑year. We are also pursuing additional mechanism-targeted larger indications including liver cancer and KRAS‑mutant tumors with leading centers including Dana‑Farber...

More updates from Beyondspring, Inc.